Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma

NCT02186249 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Bristol-Myers Squibb